Rigel Pharmaceuticals
- Country
- 🇮🇳India
- Ownership
- -
- Employees
- 147
- Market Cap
- -
- Introduction
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Rigel Pharmaceuticals Unveils Promising Final Data from GAVRETO and REZLIDHIA Clinical Trials at ASCO and EHA 2025
Final data from the Phase 1/2 ARROW study demonstrates GAVRETO's durable efficacy in RET fusion-positive NSCLC, with a 70.3% overall response rate and median overall survival of 44.3 months.
Over 120 Pipeline Therapies Target Acute Myeloid Leukemia as Research Intensifies
DelveInsight's latest report reveals a robust pipeline with 110+ companies developing 120+ therapies for acute myeloid leukemia (AML), showing significant investment in this aggressive blood cancer.
Rigel Pharmaceuticals Reports Strong Growth with TAVALISSE and REZLIDHIA in 2024, Expands Global Reach
Rigel Pharmaceuticals achieved significant revenue growth in 2024, with TAVALISSE sales increasing 12% to $104.8 million and REZLIDHIA sales growing 118% to $23.0 million.
Rigel's Fostamatinib Enrolls First Patient in Phase I Sickle Cell Disease Trial
Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase I clinical trial of fostamatinib for sickle cell disease (SCD).
FDA Grants Orphan Drug Designation to Rigel's R289 for Myelodysplastic Syndromes
The FDA has granted Orphan Drug designation to R289 for treating myelodysplastic syndromes (MDS), offering incentives for its development.
FDA Grants Fast Track Designation to Rigel's R289 for Lower-Risk Myelodysplastic Syndrome
The FDA has granted Fast Track designation to R289, Rigel Pharmaceuticals' IRAK1/4 inhibitor, for previously treated transfusion-dependent lower-risk myelodysplastic syndrome (MDS).
Pralsetinib Linked to Increased Risk of Severe Infections in NSCLC Patients
An ad-hoc analysis of the AcceleRET-Lung trial revealed a statistically significant increased risk of severe infections in patients treated with pralsetinib compared to standard of care.
Rigel Pharmaceuticals Initiates Phase Ib/II Trial of REZLIDHIA Combination Therapy for mIDH1 AML
Rigel Pharmaceuticals has enrolled the first patient in a Phase Ib/II clinical trial evaluating REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for acute myeloid leukemia (AML).
Sanofi and Denali's RIPK1 Inhibitor Fails in Phase 2 ALS Trial
Sanofi and Denali Therapeutics' investigational drug SAR443820 (DNL788), a RIPK1 inhibitor, did not meet the primary endpoint in a Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS).